{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T17:05:52Z","timestamp":1768323952047,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.eimc.2016.07.006","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T12:57:17Z","timestamp":1473080237000},"page":"16-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost\u2013effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components"],"prefix":"10.1016","volume":"36","author":[{"given":"Josep M.","family":"Llibre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Gallien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Gonzalez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arkaitz","family":"Imaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2016.07.006_bib0140","series-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","year":"2015"},{"key":"10.1016\/j.eimc.2016.07.006_bib0145","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jama.2014.8722","article-title":"Antiretroviral treatment of adult HIV infection","volume":"312","author":"G\u00fcnthard","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.eimc.2016.07.006_bib0150","article-title":"Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015)","year":"2015","journal-title":"Enf Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2016.07.006_bib0155","unstructured":"European AIDS Clinical Society. Guidelines. Version 8.0 October 2015. Available at: http:\/\/www.eacsociety.org\/ [accessed 24.12.15]."},{"key":"10.1016\/j.eimc.2016.07.006_bib0160","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1097\/QAD.0b013e3283499cd9","article-title":"Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy","author":"Llibre","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2016.07.006_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031591","article-title":"Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured hiv patients in the United States","volume":"7","author":"Sax","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2016.07.006_bib0170","doi-asserted-by":"crossref","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.eimc.2016.07.006_bib0175","first-page":"2197","article-title":"Evolution of the K65R, K103N and M184V\/I reverse transcriptase mutations in HIV-1-infected patients experiencing virological failure between 2005 and 2010","volume":"68","author":"Charpentier","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.eimc.2016.07.006_bib0180","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"Dejesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2016.07.006_bib0185","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1097\/QAD.0b013e328340a209","article-title":"A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people","volume":"24","author":"Bangsberg","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2016.07.006_bib0190","first-page":"168","article-title":"Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment","author":"Llibre","year":"2012","journal-title":"AIDS Rev"},{"key":"10.1016\/j.eimc.2016.07.006_bib0195","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eimc.2014.05.016","article-title":"Costs and cost-efficacy analysis of the 2014 GESIDA\/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults","volume":"33","author":"Blasco","year":"2015","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2016.07.006_bib0200","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1097\/QAD.0000000000000424","article-title":"Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir+emtricitabine\/lamivudine+efavirenz administered on a multiple tablet therapy","volume":"28","author":"Blanco","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2016.07.006_bib0205","doi-asserted-by":"crossref","first-page":"e0147821","DOI":"10.1371\/journal.pone.0147821","article-title":"Cost\u2013effectiveness of single- versus generic multiple-tablet regimens for treatment of HIV-1 infection in the United States","volume":"11","author":"Sweet","year":"2016","journal-title":"PLOS ONE"},{"key":"10.1016\/j.eimc.2016.07.006_bib0210","first-page":"2239","article-title":"Class-sparing regimens for initial treatment of HIV-1 infection","volume":"358","author":"Riddler","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2016.07.006_bib0215","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/QAI.0b013e3181cae4a1","article-title":"Prospective, randomized, open label trial of Efavirenz vs. Lopinavir\/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell\/mm3 in Mexico","volume":"53","author":"Sierra-Madero","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.eimc.2016.07.006_bib0220","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/QAD.0b013e32835cb997","article-title":"Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002\u20132009","volume":"27","year":"2013","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2016.07.006_bib0225","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1473-3099(12)70134-2","article-title":"Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement","volume":"12","author":"Crawford","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eimc.2016.07.006_bib0230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/hiv.12097","article-title":"Antiretroviral treatment-based cost saving interventions may offset expenses for new patients and earlier treatment start","volume":"15","author":"Angeletti","year":"2014","journal-title":"HIV Med"},{"key":"10.1016\/j.eimc.2016.07.006_bib0235","doi-asserted-by":"crossref","first-page":"e44774","DOI":"10.1371\/journal.pone.0044774","article-title":"Cost\u2013effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal","volume":"7","author":"Arag\u00e3o","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.eimc.2016.07.006_bib0240","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(13)62187-X","article-title":"Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial","volume":"383","author":"Amin","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2016.07.006_bib0245","doi-asserted-by":"crossref","first-page":"84","DOI":"10.7326\/0003-4819-158-2-201301150-00002","article-title":"Economic savings versus health losses: the cost\u2013effectiveness of generic antiretroviral therapy in the United States","volume":"158","author":"Walensky","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2016.07.006_bib0250","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2016.07.006_bib0255","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","author":"Cohen","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2016.07.006_bib0260","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2016.07.006_bib0265","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2016.07.006_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M14-0293","article-title":"Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data","volume":"161","author":"Mollan","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16302361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X16302361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T19:43:46Z","timestamp":1657223026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X16302361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0213005X16302361"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2016.07.006","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost\u2013effectiveness of initial antiretroviral treatment administered as single vs. multiple tablet regimens with the same or different components","name":"articletitle","label":"Article Title"},{"value":"Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. All rights reserved.","name":"copyright","label":"Copyright"}]}}